Key Takeaways J&J's MedTech sales improved for two straight quarters, led by Cardiovascular, Surgery and Vision businesses.J&J's Cardiovascular segment rose 17.4% in the first nine months of 2025, boosted by Abiomed and Shockwave.J&J expects continued MedTech momentum despite China VBP pressure, with growth driven by new product adoption.Johnson & Johnson's (JNJ) medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment acc ...

New CAPLYTAо (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in adjunctive major depressive disorder (aMDD) to be presented SPRAVATOо (esketamine) effects on anhedonia in treatment-resistant depression (TRD) Ц Phase 3 data post-hoc analyses to be presented Comparative tolerability of adjunctive seltorexant vs. adjunctive quetiapine XR in major depressive disorder (MDD) with insomnia symptoms Ц new Phase 3 metabolic analyses will also be presented TITUSVILLE, N.J., Jan. 13, 2026 /P ...

Investment Rating - The report maintains a positive outlook on the development of dual and triple antibodies in multiple myeloma (MM) and recommends monitoring the progress of TCE monotherapy and combination therapies in MM, including the EMD population [1][15]. Core Insights - The 67th ASH Annual Meeting highlighted significant advancements in hematology, particularly in the treatment of multiple myeloma, diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [31]. - In multiple myeloma, the Tec-Dara combination therapy demonstrated a 36-month overall survival (OS) rate of 83.3%, significantly higher than the 65.0% in the control group, with a hazard ratio (HR) of 0.46 [32]. - The MSD ROR1 ADC showed promising first-line potential in DLBCL, with 24-month OS and progression-free survival (PFS) rates of 94% and 84%, respectively, outperforming existing treatments [33]. - Eli Lilly's Pirto showed improved PFS and OS trends compared to BR, but the executive admitted it may not become the first-line choice for CLL/SLL due to limited follow-up data and current treatment practices favoring covalent BTK inhibitors [34]. Summary by Sections 1. R/R MM: Focus on Dual/Triple Antibodies and TCE Therapies - Johnson & Johnson's BCMA/CD3+daratumumab therapy received FDA's "National Priority Voucher," reducing review time to 1-2 months, showing excellent efficacy in high-risk patients [7][15]. - IBI3003 from Innovent demonstrated an overall response rate (ORR) of 83.3% in high-risk patients, with a 100% minimal residual disease (MRD) negative rate in those achieving complete response (CR) [16]. - AstraZeneca's AZD0120 (BCMA/CD19 CAR-T) is projected to exceed $5 billion in sales, with a 100% ORR in treated patients [20][21]. 2. DLBCL: MSD ROR1 ADC Shows First-Line Potential - The MSD ROR1 ADC demonstrated a 24-month OS rate of 94% and a PFS rate of 84%, outperforming R-CHOP and Pola-CHP treatments [22][23]. - In high-risk populations, the ORR was 75% for patients with extramedullary disease (EMD), with a 100% ORR in the 1200 µg/kg dose group [23]. 3. CLL/SLL: Pirto May Not Become First-Line Choice - Pirto vs BR showed a 24-month PFS of 93.4% vs 70.7%, but the data is still immature, with a median follow-up of 28 months [25][27]. - The safety profile of Pirto indicated a 40% incidence of grade 3 or higher treatment-emergent adverse events (TEAEs), compared to 67.4% for BR [25][27].

Johnson & Johnson (JNJ) closed the most recent trading day at $209.72, moving +2.61% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.16%. On the other hand, the Dow registered a gain of 0.17%, and the technology-centric Nasdaq increased by 0.26%. Prior to today's trading, shares of the world's biggest maker of health care products had lost 3.4% lagged the Medical sector's gain of 2.84% and the S&P 500's gain of 1.89%.The upcoming earnings release of Johnson & Johnson will ...

Johnson & Johnson convinced Delaware's highest court to throw out part of a $1 billion damages award for breaching its 2019 agreement to buy Auris Health, a maker of surgical robots. ...

The U.S. stock market today, Monday, January 12th, 2026, was largely influenced by significant political developments, creating a mixed trading environment. The Dow Jones Industrial Average (^DJI) was up 24.69 (0.0499%) points, reflecting a modest gain amidst underlying market uncertainty. This comes as Dow Futures (YM=F) also showed a slight increase of 26.00 (0.0523%) points.The primary narrative driving market sentiment was the unfolding situation surrounding the Federal Reserve. News broke that the Just ...

Question-and-Answer SessionLet me just open up the conversation, we're coming off of a year with significant outperformance for the stock, some really impressive kind of underlying fundamentals, would love just to hear about your top priorities for the company as we enter 2026.Joaquin DuatoCEO & Chairman Thank you. So first, thank you for organizing this impressive meeting. Every year JPMorgan does a very good job in bringing us all together and kicking off the year. So thank you for doing that. And thank y ...

Johnson & Johnson (NYSE:JNJ) FY Conference January 12, 2026 11:15 AM ET Company ParticipantsJoaquin Duato - Chairman and CEOChris Schott - Managing Director and Senior Equity Research AnalysChris SchottGood morning. I'm Chris Schott from JPMorgan, and it's my pleasure to be hosting this fireside discussion with Joaquin Duato, the Chairman and CEO of J&J. Joaquin, happy New Year.Joaquin DuatoThank you.Chris SchottGreat speaking with you today. Do you want to just open up the conversation? We're coming off of ...

In this articleJNJXBIPFEBMYLLYThe J.P. Morgan conference draws thousands of investors, analysts, and executives. Above, a JPMorgan Chase branch in San Francisco, in 2021. (David Paul Morris/Bloomberg)The first morning of the biggest healthcare conference of the year seems to have come and gone without any major deal announcements. ...

Federal Reserve Investigation - A criminal investigation has been launched into Federal Reserve Chair Jerome Powell regarding the renovation of the Fed's Washington headquarters and potential false statements made to Congress about the project's scope [2][3] - The investigation, approved by Jeanine Pirro, includes analysis of Powell's public statements and spending records [3] - The renovation project, which began in 2022, is approximately $700 million over budget and involves modernizing the Marriner S. Eccles Building and another building, both of which have not been comprehensively renovated since their construction nearly 100 years ago [5] Allegiant Travel Acquisition - Allegiant Travel Co. has agreed to acquire Sun Country Airlines in a cash-and-stock deal valued at approximately $1.5 billion, including net debt [8] - Under the terms of the agreement, Sun Country shareholders will receive 0.1557 shares of Allegiant common stock and $4.10 in cash for each share, implying a total value of $18.89 per share, representing a 19.8% premium over Sun Country's closing price of $15.77 [8] Meta's Compliance with Age Restrictions - Meta has removed over 550,000 accounts of Australian children from its platforms to comply with a social media ban for users under 16 [9][10] - The removal included 330,000 users from Instagram, 173,000 from Facebook, and 39,000 from Threads, following the implementation of the ban on December 10, 2025 [10] - Meta has indicated that early data suggests the ban is not effectively improving teen safety or wellbeing, citing inconsistent age-verification measures across platforms [11]